Next Article in Journal
Genomic Insights into the Molecular Basis of Broad Host Adaptability of the Entomopathogenic Fungus Conidiobolus coronatus (Entomophthoromycotina)
Previous Article in Journal
Verticillium-like Anamorphic Fungi in Sordariomycetes from Southwestern China: Two New Taxa and a New Record
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System

1
Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
2
Veterans Medical Research Foundation, San Diego, CA 92161, USA
3
Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
4
Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA
5
Department of Infectious Diseases, J. Craig Venter Institute, La Jolla, CA 92037, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors also contributed equally to this work.
J. Fungi 2025, 11(8), 599; https://doi.org/10.3390/jof11080599
Submission received: 12 July 2025 / Revised: 8 August 2025 / Accepted: 14 August 2025 / Published: 19 August 2025
(This article belongs to the Section Fungal Pathogenesis and Disease Control)

Abstract

Coccidioides species are thermally dimorphic fungal pathogens that cause coccidioidomycosis (Valley Fever) primarily in North and South America. Coccidioides grow as hyphae that differentiate into arthroconidia, which can be aerosolized upon soil disturbance, and inhaled by the mammalian host to cause pulmonary infections with occasional dissemination to other organs. In the context of mouse models, current methods of infection include intranasal, intravenous, and intraperitoneal delivery of the arthroconidia into mice. To explore an aerosol route of infection, we compared the intranasal method with aerosolization using the Glass-Col Inhalation Exposure System (IES). Infection with a dose of 2 × 106 CFU/mL, nebulized in 5 mL of PBS, but not in water, was able to infect mice, albeit inconsistently, compared to intranasal challenge. Arthroconidia were detected inside the IES after the nebulization and decontamination cycles. These studies highlight some of the challenges with aerosolization of Coccidioides arthroconidia and serve as a reminder about biosafety considerations for use of the IES to aerosolize pathogens.

1. Introduction

Coccidioides are pathogenic dimorphic fungi endemic to the western United States, Central America, and South America, and a causative agent of coccidioidomycosis, a pulmonary disease commonly known as Valley Fever [1,2]. Infection occurs after inhalation of aerosolized arthroconidia released from soil disturbances such as weather events, construction, mining, and farming. While infections may be asymptomatic or produce mild self-limited flu-like symptoms, a subset of individuals develop pneumonia, and disseminated infections of peripheral organs and the central nervous system [3].
Rodents are naturally infected in endemic areas and laboratory mice are used commonly to model coccidioidomycosis. The intranasal (I.N.) route of infection is commonly employed for infecting laboratory mice with a wide range of pathogens including influenza, SARS-CoV-2, Streptococcus pneumoniae, Histoplasma capsulatum, and Coccidioides species [4,5,6,7,8,9,10]. This technique requires anesthesia of mice with ketamine/xylazine or isoflurane, followed by intranasal (I.N.) instillation of a pathogen suspended in phosphate-buffered saline (PBS).
Coccidioides is an airborne pathogen, and infection is initiated by the inhalation of dry aerosolized arthroconidia, not respiratory droplets. While I.N. infection models using arthroconidia suspended in PBS effectively induce infection in mice, they may not perfectly replicate the natural exposure route, and anesthetics can potentially influence the immune system and disrupt physiological homeostasis [11]. As an alternative method to I.N. infection models, inhalation exposure systems have been successfully used for some airborne pathogens, such as Mycobacterium tuberculosis and SARS-CoV-2 [12,13,14]. We hypothesized that such a system could be used to nebulize Coccidioides arthroconidia and would serve as a physiologically relevant infection model, while eliminating possible confounding effects of anesthesia. In addition, since the instrument can hold up to 50 mice, investigators could simultaneously infect multiple strains of mice that might respond differently to anesthetics without concern about the anesthesia being another variable.
In this study, utilizing the Glas-Col Inhalation Exposure System (IES), we tested if nebulization of arthroconidia would be a higher throughput and reproducible method to induce murine coccidioidomycosis. We compared IES nebulization to intranasal infection, evaluating disease-free survival, local and systemic infection burdens, and biosafety considerations. This study seeks to establish a refined roadmap for future Coccidioides infection models.

2. Methods

2.1. Mice

In this study, 8–20-week-old male and female C57BL/6J mice were housed in pathogen-free conditions with unrestricted access to food and water. Mouse experiments were conducted in an ABSL3 facility in accordance with institutional biosafety regulations and the regulatory standards of the Institutional Animal Care and Use Committee.

2.2. Fungal Cultures

The Coccidioides immitis RS fungal strain (BEI, NR-48942) was plated from frozen stocks and cultured on 2X Glucose Yeast Extract (2X GYE) agar plates (2% glucose [Sigma-Aldrich, Burlington, MA, USA, #G8270-5KG], 1% yeast extract [Gibco #DF210929] (Waltham, MA, USA), agar [Gibco #DF0145-17-0]). Cultures grew for 4–6 weeks at 30 °C to induce arthroconidium formation. Arthroconidia were harvested as previously described [15]. Harvested stocks were stored at 4 °C, and viability was periodically assessed by plating serial dilutions on 2X GYE agar, incubating for 4 days at 30 °C, and quantifying colony-forming units (CFUs).

2.3. Aerosolization of Pathogens

Coccidioides immitis R.S. was nebulized in 5 mL of either MilliQ H2O or PBS in the Glas-Col Inhalation Exposure SystemTM (IES; Terre Haute, IN, USA)) under the following parameters: 25 min of nebulization, 40 min of cloud decay, and 15 min of decontamination. Mice or agar plates were placed in the chamber for the entire duration of the IES run after which plates were removed to a humidified incubator at 30 °C with a mixture of 5% CO2 and 95% ambient air. Mouse weights were monitored after exposure, and they were euthanized if and when they lost >15% of their starting weight for three days in a row, or more than 20% bodyweight, whichever came first.

2.4. Intranasal Infection Model

Mice were anesthetized (3–5% isoflurane at 5 L/min and O2 at 2 L/min) and infected with 100 colony-forming units (CFUs) intranasally in a total volume of 50 µL of PBS. Weight loss was monitored as above, and we used the same criteria for euthanasia.

2.5. Fungal Titers

Lungs and spleen were placed in 2 mL SafeLock microtubes (Eppendorf) containing 1 mL of PBS and a 5 mm stainless steel bead (Qiagen) for tissue disruption using a TissueLyser II (Qiagen). Samples were serially diluted and plated on 2× GYE agar plates that were incubated at 30 °C and colonies were enumerated.

2.6. Statistical Analysis

Data were represented as the geometric mean  ±  standard error of the mean (SEM). Comparison of survival curves were performed via Gehan–Breslow–Wilcoxon test. All statistical analyses were performed using GraphPad Prism 10.4.1 (San Diego, CA, USA). p < 0.05 was considered statistically significant.

3. Results

Nebulization of Coccidioides Inconsistently Infected Mice

To first confirm that Coccidioides could be nebulized into the aerosol chamber, Coccidioides immitis RS arthroconidia at 5000 CFU/mL were prepared in MilliQ H2O, which is the suggested diluent per manufacturer’s instructions, and then nebulized. Agar plates were placed inside baskets, outside of the baskets within the IES, outside of the IES, and on the floor adjacent to the IES to confirm containment of the pathogen within the IES, and then incubated at 30 °C. Only the plates from inside the IES had growth of the fungus; none of the plates that were outside of the IES or on the floor adjacent to the IES had any growth, demonstrating a low risk of leakage of the nebulized arthroconidia outside the IES (Figure 1A).
To examine the utility of the IES for infecting mice, we used C57BL/6J mice which are highly susceptible to coccidioidomycosis [16]. We compared our standard intranasal infection, to the IES starting with a nebulization dose of 5000 CFU/mL in 5 mL MilliQ H2O. We incrementally increased the number of aerosolized arthroconidia to 107 CFU but no mice were infected when MilliQ H2O was used as the diluent (Figure 1 and Table 1).
Next, we tested PBS as a diluent since it is used in the I.N. route of infection. Surprisingly, when PBS was used as the diluent, after nebulization of 106 CFU/mL, approximately 50% of mice were infected, and 80% were successfully infected at 2 × 106 CFU/mL (Table 1). These data suggest that MilliQ H2O impairs infectivity by aerosolization but even in PBS a relatively high number of arthroconidia were required for efficient infection of mice.
To investigate the efficiency of the decontamination cycle of the IES after high dose (a total of 107 CFU) of Coccidioides nebulization, the interior of the chamber, including baskets, trays, and walls, was swabbed for culture. Arthroconidia were detected from those surfaces, indicating that the decontamination cycle does not completely remove nebulized arthroconidia.
Next, we compared the two methods of infecting the lungs of C57BL/6J mice. Mice that were infected intranasally with 100 CFU reached criteria for euthanasia (>15% weight loss for >3 days or >20% weight loss) between days 10 and 13 after infection (Figure 1B). In contrast, mice infected by nebulizing 5 × 106 CFU in PBS did not start to reach that endpoint until 15 days post-infection, and only 10 out of 19 mice were infected 17 days post-infection (Figure 1B). Using the same IES infection cycle, titers in the lung and spleen were assessed as a measure of the severity of the pneumonia and the amount of dissemination, respectively, at day 16 P.I, which correlated with endpoint disease as we defined (Figure 1C). From the IES cohort, only 4/9 IES mice had evidence of pulmonary infection, and all the infected mice had disseminated infections. In contrast, all mice that were infected intranasally with 100 CFU had evidence of infection in the lung and dissemination to the spleen (Figure 1D).

4. Discussion

Authentic modeling of human respiratory infections in mice remains an important goal for studying the pathogenesis of pulmonary infections. While intranasal infection provides an effective route for pulmonary infection, it is potentially complicated by the need to anesthetize mice, possible differences in lung distribution resulting from I.N. or aerosol infection, and potential for subtle changes to the immune response in the lung due to anesthesia. Consequently, in this study, we developed a protocol for nebulizing Coccidioides, a soil-derived and airborne fungal pathogen that is naturally acquired by inhaling arthroconidia. This study sought to establish a protocol for aerosolizing Coccidioides to better mimic the natural route of infection for humans.
Both intranasal and aerosol infection routes generated productive infections, but with the IES we could not infect any mice using the recommended fluid for suspending the inoculum, and only after switching to PBS and increasing the inoculum to 106 CFU/mL did we infect about half of the mice that were exposed. Even that infection was less severe than the I.N. infection as measured by survival and by quantitative culture of the lungs and spleens. Disappointingly, there was still one log spread in the CFU of the IES-infected mice. PBS is not recommended by the maker of the instrument as the salts may crystallize in the nozzles, so this method of infecting mice with arthroconidia does not appear robust.
The lower colony counts of C. immitis from the lungs of mice infected by the aerosol route may have been due to a more vigorous innate immune response in their lungs, but more likely they were because a smaller number of organisms were inhaled than entered the lung after I.N. instillation. We are also concerned that despite exhaustion of the atmosphere in the IES device, there were residual viable Coccidioides on the inside of the IES post-decontamination cycle. Coccidioidomycosis is a biohazard for microbiologists in clinical laboratories [8], and the IES may need chemical disinfection after the end of a run so that subsequent users would not risk exposure to arthroconidia. There is no comparable risk when isoflurane or ketamine is used for I.N. infections inside a biosafety cabinet. Although it is an advantage to be able to infect many mice simultaneously using the IES, to ensure a high percentage will be infected, it is necessary to harvest >107 arthroconidia, a formidable task.
These findings collectively highlight the complexity of modeling this respiratory fungal infection and the trade-offs between physiological relevance, experimental consistency, and safety. While the I.N. model offers uniform infection, it may exaggerate disease severity, potentially due to anesthesia-related immunomodulation, though this is a hypothetical risk. The IES has been used successfully to infect mice with other respiratory pathogens, but we were unable to use it to reliably infect mice by aerosolization. We were unable to find a protocol that was compatible with the instrument that uniformly infected the mice. In addition, the increased biohazards associated with residual contamination of the instrument, including the need to grow and harvest a large quantity of the infectious mold for each experiment and ensuring biosafety, is of significant concern. As it stands, we cannot recommend adoption of this model to study pulmonary coccidioidomycosis.

Author Contributions

Conceptualization: J.R.E., P.R., K.P.S.Y., M.T., A.F.C., J.F., T.N.K., H.M.H., S.B. and B.A.C.; Methodology: J.R.E., P.R., K.P.S.Y., M.T., S.B. and B.A.C.; Investigation: J.R.E., P.R., K.P.S.Y., M.T., S.B. and B.A.C.; Visualization: J.R.E., P.R., K.P.S.Y. and M.T.; Funding Acquisition: A.F.C., J.F., T.N.K., H.M.H., S.B. and B.A.C.; Supervision: A.F.C., J.F., T.N.K., H.M.H., S.B. and B.A.C.; Writing (original draft): J.R.E., P.R., J.F., T.N.K., S.B. and B.A.C.; Writing (reviewing and editing): J.R.E., P.R., K.P.S.Y., M.T., A.F.C., J.F., T.N.K., H.M.H., S.B. and B.A.C. All authors have read and agreed to the published version of the manuscript.

Funding

National Institutes of Health grant U19AI166059.

Acknowledgments

The authors would like to thank the NIH Coccidioidomycosis Collaborative Research Centers (CCRC) and the members of the UCLA-UCSD CCRC for their comments and suggestions for this study. We are grateful for insightful discussions with Aristea Lubar.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Brown, J.; Benedict, K.; Park, B.J.; Thompson, G.R., 3rd. Coccidioidomycosis: Epidemiology. Clin. Epidemiol. 2013, 5, 185–197. [Google Scholar] [PubMed]
  2. Galgiani, J.N.; Kauffman, C.A. Coccidioidomycosis and Histoplasmosis in Immunocompetent Persons. N. Engl. J. Med. 2024, 390, 536–547. [Google Scholar] [CrossRef] [PubMed]
  3. Wang, C.Y.; Jerng, J.S.; Ko, J.C.; Lin, M.F.; Hsiao, C.H.; Lee, L.N.; Hsueh, P.-R.; Kuo, S.-H. Disseminated coccidioidomycosis. Emerg. Infect. Dis. 2005, 11, 177–179. [Google Scholar] [CrossRef] [PubMed]
  4. To, E.E.; Erlich, J.; Liong, F.; Luong, R.; Liong, S.; Bozinovski, S.; Seow, H.J.; O’lEary, J.J.; Brooks, D.A.; Vlahos, R.; et al. Intranasal and epicutaneous administration of Toll-like receptor 7 (TLR7) agonists provides protection against influenza A virus-induced morbidity in mice. Sci. Rep. 2019, 9, 2366. [Google Scholar] [CrossRef] [PubMed]
  5. Suarez-Alvarez, R.O.; Sahaza, J.H.; Berzunza-Cruz, M.; Becker, I.; Curiel-Quesada, E.; Perez-Torres, A.; Reyes-Montes, M.d.R.; Taylor, M.L. Dimorphism and Dissemination of Histoplasma capsulatum in the Upper Respiratory Tract after Intranasal Infection of Bats and Mice with Mycelial Propagules. Am. J. Trop. Med. Hyg. 2019, 101, 716–723. [Google Scholar] [CrossRef] [PubMed]
  6. Dileepan, T.; Smith, E.D.; Knowland, D.; Hsu, M.; Platt, M.; Bittner-Eddy, P.; Cohen, B.; Southern, P.; Latimer, E.; Harley, E.; et al. Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. J. Clin. Investig. 2016, 126, 303–317. [Google Scholar] [CrossRef] [PubMed]
  7. Jeon, D.; Kim, S.H.; Kim, J.; Jeong, H.; Uhm, C.; Oh, H.; Cho, K.; Cho, Y.; Park, I.H.; Oh, J.; et al. Discovery of a new long COVID mouse model via systemic histopathological comparison of SARS-CoV-2 intranasal and inhalation infection. Biochim. Biophys. Acta Mol. Basis Dis. 2024, 1870, 167347. [Google Scholar] [CrossRef] [PubMed]
  8. Porte, L.; Valdivieso, F.; Wilmes, D.; Gaete, P.; Diaz, M.C.; Thompson, L.; Munita, J.; Alliende, R.; Varela, C.; Rickerts, V.; et al. Laboratory exposure to Coccidioides: Lessons learnt in a non-endemic country. J. Hosp. Infect. 2019, 102, 461–464. [Google Scholar] [CrossRef] [PubMed]
  9. Shubitz, L.; Peng, T.; Perrill, R.; Simons, J.; Orsborn, K.; Galgiani, J.N. Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA. Infect. Immun. 2002, 70, 3287–3289. [Google Scholar] [CrossRef] [PubMed]
  10. Viriyakosol, S.; Jimenez Mdel, P.; Gurney, M.A.; Ashbaugh, M.E.; Fierer, J. Dectin-1 is required for resistance to coccidioidomycosis in mice. mBio 2013, 4, e00597-12. [Google Scholar] [CrossRef] [PubMed]
  11. Stollings, L.M.; Jia, L.J.; Tang, P.; Dou, H.; Lu, B.; Xu, Y. Immune Modulation by Volatile Anesthetics. Anesthesiology 2016, 125, 399–411. [Google Scholar] [CrossRef] [PubMed]
  12. Fumagalli, V.; Rava, M.; Marotta, D.; Di Lucia, P.; Laura, C.; Sala, E.; Grillo, M.; Bono, E.; Giustini, L.; Perucchini, C.; et al. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Sci. Immunol. 2022, 7, eabl9929. [Google Scholar] [CrossRef] [PubMed]
  13. Kumar, P.; Schelle, M.W.; Jain, M.; Lin, F.L.; Petzold, C.J.; Leavell, M.D.; Leary, J.A.; Cox, J.S.; Bertozzi, C.R. PapA1 and PapA2 are acyltransferases essential for the biosynthesis of the Mycobacterium tuberculosis virulence factor sulfolipid-1. Proc. Natl. Acad. Sci. USA 2007, 104, 11221–11226. [Google Scholar] [CrossRef] [PubMed]
  14. Stutz, M.D.; Allison, C.C.; Ojaimi, S.; Preston, S.P.; Doerflinger, M.; Arandjelovic, P.; Whitehead, L.; Bader, S.M.; Batey, D.; Asselin-Labat, M.-L.; et al. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis. Immunity 2021, 54, 1758–1771.e7. [Google Scholar] [CrossRef] [PubMed]
  15. Mead, H.L.; Van Dyke, M.C.C.; Barker, B.M. Proper Care and Feeding of Coccidioides: A Laboratorian’s Guide to Cultivating the Dimorphic Stages of C. immitis and C. posadasii. Curr. Protoc. Microbiol. 2020, 58, e113. [Google Scholar] [CrossRef] [PubMed]
  16. Kirkland, T.N.; Fierer, J. Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection. Infect. Immun. 1983, 40, 912–916. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Aerosolization of Coccidioides arthroconidia to infect mice. (A) Open agar plates were placed as indicated throughout the chamber for the duration of the infection cycle, where C. immitis RS arthroconidia were nebulized in 5 mL of MilliQ H2O. Individual colonies counted from agar plates are represented. (B) Disease-free survival curves of mice infected by nebulizing 107 CFUs in 5 mL of PBS or 100 CFUs intranasally. Mean  ±  SEM of n  =  8–10 mice are shown with statistical analyses performed via a Gehan–Breslow–Wilcoxon test. **** indicates p < 0.0001. (C,D) Lung or spleen homogenates of mice infected at (C) 1 × 106 CFU/mL (5 mL total volume) of PBS collected 16 days P.I. or (D) 100 CFUs intranasally collected 15 days P.I. Data are represented as mean  ±  SEM of colony counts from n  =  8–10 spleens or lungs, where n represents one organ from one individual mouse.
Figure 1. Aerosolization of Coccidioides arthroconidia to infect mice. (A) Open agar plates were placed as indicated throughout the chamber for the duration of the infection cycle, where C. immitis RS arthroconidia were nebulized in 5 mL of MilliQ H2O. Individual colonies counted from agar plates are represented. (B) Disease-free survival curves of mice infected by nebulizing 107 CFUs in 5 mL of PBS or 100 CFUs intranasally. Mean  ±  SEM of n  =  8–10 mice are shown with statistical analyses performed via a Gehan–Breslow–Wilcoxon test. **** indicates p < 0.0001. (C,D) Lung or spleen homogenates of mice infected at (C) 1 × 106 CFU/mL (5 mL total volume) of PBS collected 16 days P.I. or (D) 100 CFUs intranasally collected 15 days P.I. Data are represented as mean  ±  SEM of colony counts from n  =  8–10 spleens or lungs, where n represents one organ from one individual mouse.
Jof 11 00599 g001
Table 1. List of tests performed through nebulization of Coccidioides immitis RS arthroconidia.
Table 1. List of tests performed through nebulization of Coccidioides immitis RS arthroconidia.
Dose (CFU/mL)Nebulized Dose (CFU)DiluentTestInfected
5 × 1032.5 × 104H2OAgar platesGrowth
5 × 1032.5 × 104H2OMice1/49
5 × 1042.5 × 105H2OMice0/50
2 × 1061 × 107H2OMice0/50
2 × 1061 × 107PBSMice4/5
1 × 1065 × 106PBSMice10/19
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Erlich, J.R.; Rodriguez, P.; Yau, K.P.S.; Tate, M.; Carlin, A.F.; Fierer, J.; Kirkland, T.N.; Hoffman, H.M.; Beyhan, S.; Croker, B.A. Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System. J. Fungi 2025, 11, 599. https://doi.org/10.3390/jof11080599

AMA Style

Erlich JR, Rodriguez P, Yau KPS, Tate M, Carlin AF, Fierer J, Kirkland TN, Hoffman HM, Beyhan S, Croker BA. Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System. Journal of Fungi. 2025; 11(8):599. https://doi.org/10.3390/jof11080599

Chicago/Turabian Style

Erlich, Jonathan Rodrigo, Priscila Rodriguez, Ka Pui Sharon Yau, Matthew Tate, Aaron F. Carlin, Joshua Fierer, Theo N. Kirkland, Hal M. Hoffman, Sinem Beyhan, and Ben A. Croker. 2025. "Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System" Journal of Fungi 11, no. 8: 599. https://doi.org/10.3390/jof11080599

APA Style

Erlich, J. R., Rodriguez, P., Yau, K. P. S., Tate, M., Carlin, A. F., Fierer, J., Kirkland, T. N., Hoffman, H. M., Beyhan, S., & Croker, B. A. (2025). Development of a Mouse Model of Coccidioidomycosis Using an Inhalation Exposure System. Journal of Fungi, 11(8), 599. https://doi.org/10.3390/jof11080599

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop